ArticleUrolithiasis2025
Efficacy of methylene blue-assisted tract visualization in ultrasound-guided percutaneous nephrolithotomy: a salvage technique for failed renal access.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We propose using methylene blue with ultrasound-guided percutaneous nephrolithotomy (US-PCNL) as a salvage method when ultrasonography access is challenging, to prevent the necessity of creating a new tract or access failure. We retrospectively evaluated adult patients who underwent US-PCNL over two years by a single surgeon. Patients were divided into two groups based on methylene blue usage. In cases with challenging renal access, diluted methylene blue was injected via the ureteral catheter, and the nephroscope was used to locate the parenchymal defect by visualizing the blue area. Among 120 patients, 34 (28.3%) required methylene blue for renal access. Recurrent stones (70.6% vs. 47.7%; p-value: 0.023) and previous PCNL (41.2% vs. 18.6%; p-value: 0.010) were more common in these patients. All achieved successful access with a single tract. Although access time (median: 235 vs. 160 s; p-value: < 0.001) and operative duration (median: 90 vs. 85 min; p-value: 0.023) were statistically longer when methylene blue was used, the differences were not clinically significant. Analgesic use, hospital stay, hemoglobin drop, and creatinine rise were similar between groups. Stone-free rates after the first session were 50.0% with methylene blue and 57.0% without it (p-value: 0.489). Residual stone rates requiring ancillary procedures were higher when methylene blue was needed (20.6% vs. 9.4%), but the difference was not statistically significant (p-value: 0.126). Complication rates were similar between the groups. Methylene blue injection into the ureteral catheter is a safe and effective procedure for US-PCNL, reducing access failure and the need for new tracts.
Indexed as
Identifiers
40121572What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.